197 related articles for article (PubMed ID: 32910065)
1. Mechanistic differences underlying HIV latency in the gut and blood contribute to differential responses to latency-reversing agents.
Telwatte S; Kim P; Chen TH; Milush JM; Somsouk M; Deeks SG; Hunt PW; Wong JK; Yukl SA
AIDS; 2020 Nov; 34(14):2013-2024. PubMed ID: 32910065
[TBL] [Abstract][Full Text] [Related]
2. Gut and blood differ in constitutive blocks to HIV transcription, suggesting tissue-specific differences in the mechanisms that govern HIV latency.
Telwatte S; Lee S; Somsouk M; Hatano H; Baker C; Kaiser P; Kim P; Chen TH; Milush J; Hunt PW; Deeks SG; Wong JK; Yukl SA
PLoS Pathog; 2018 Nov; 14(11):e1007357. PubMed ID: 30440043
[TBL] [Abstract][Full Text] [Related]
3. High-throughput Characterization of HIV-1 Reservoir Reactivation Using a Single-Cell-in-Droplet PCR Assay.
Yucha RW; Hobbs KS; Hanhauser E; Hogan LE; Nieves W; Ozen MO; Inci F; York V; Gibson EA; Thanh C; Shafiee H; El Assal R; Kiselinova M; Robles YP; Bae H; Leadabrand KS; Wang S; Deeks SG; Kuritzkes DR; Demirci U; Henrich TJ
EBioMedicine; 2017 Jun; 20():217-229. PubMed ID: 28529033
[TBL] [Abstract][Full Text] [Related]
4. Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4(+) T Cells from Aviremic Patients.
Spivak AM; Bosque A; Balch AH; Smyth D; Martins L; Planelles V
Antimicrob Agents Chemother; 2015 Oct; 59(10):5984-91. PubMed ID: 26169416
[TBL] [Abstract][Full Text] [Related]
5. Latency reversal agents affect differently the latent reservoir present in distinct CD4+ T subpopulations.
Grau-Expósito J; Luque-Ballesteros L; Navarro J; Curran A; Burgos J; Ribera E; Torrella A; Planas B; Badía R; Martin-Castillo M; Fernández-Sojo J; Genescà M; Falcó V; Buzon MJ
PLoS Pathog; 2019 Aug; 15(8):e1007991. PubMed ID: 31425551
[TBL] [Abstract][Full Text] [Related]
6. Tissue-specific differences in HIV DNA levels and mechanisms that govern HIV transcription in blood, gut, genital tract and liver in ART-treated women.
Moron-Lopez S; Xie G; Kim P; Siegel DA; Lee S; Wong JK; Price JC; Elnachef N; Greenblatt RM; Tien PC; Roan NR; Yukl SA
J Int AIDS Soc; 2021 Jul; 24(7):e25738. PubMed ID: 34235864
[TBL] [Abstract][Full Text] [Related]
7. Multiply spliced HIV RNA is a predictive measure of virus production ex vivo and in vivo following reversal of HIV latency.
Zerbato JM; Khoury G; Zhao W; Gartner MJ; Pascoe RD; Rhodes A; Dantanarayana A; Gooey M; Anderson J; Bacchetti P; Deeks SG; McMahon J; Roche M; Rasmussen TA; Purcell DF; Lewin SR
EBioMedicine; 2021 Mar; 65():103241. PubMed ID: 33647768
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneous HIV-1 Reactivation Patterns of Disulfiram and Combined Disulfiram+Romidepsin Treatments.
Kula A; Delacourt N; Bouchat S; Darcis G; Avettand-Fenoel V; Verdikt R; Corazza F; Necsoi C; Vanhulle C; Bendoumou M; Burny A; De Wit S; Rouzioux C; Rohr O; Van Lint C
J Acquir Immune Defic Syndr; 2019 Apr; 80(5):605-613. PubMed ID: 30768485
[TBL] [Abstract][Full Text] [Related]
9. The Pathway To Establishing HIV Latency Is Critical to How Latency Is Maintained and Reversed.
Rezaei SD; Lu HK; Chang JJ; Rhodes A; Lewin SR; Cameron PU
J Virol; 2018 Jul; 92(13):. PubMed ID: 29643247
[TBL] [Abstract][Full Text] [Related]
10. Heterogeneity in HIV and cellular transcription profiles in cell line models of latent and productive infection: implications for HIV latency.
Telwatte S; Morón-López S; Aran D; Kim P; Hsieh C; Joshi S; Montano M; Greene WC; Butte AJ; Wong JK; Yukl SA
Retrovirology; 2019 Nov; 16(1):32. PubMed ID: 31711503
[TBL] [Abstract][Full Text] [Related]
11. Posttranscriptional Regulation of HIV-1 Gene Expression during Replication and Reactivation from Latency by Nuclear Matrix Protein MATR3.
Sarracino A; Gharu L; Kula A; Pasternak AO; Avettand-Fenoel V; Rouzioux C; Bardina M; De Wit S; Benkirane M; Berkhout B; Van Lint C; Marcello A
mBio; 2018 Nov; 9(6):. PubMed ID: 30425153
[TBL] [Abstract][Full Text] [Related]
12. An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression.
Darcis G; Kula A; Bouchat S; Fujinaga K; Corazza F; Ait-Ammar A; Delacourt N; Melard A; Kabeya K; Vanhulle C; Van Driessche B; Gatot JS; Cherrier T; Pianowski LF; Gama L; Schwartz C; Vila J; Burny A; Clumeck N; Moutschen M; De Wit S; Peterlin BM; Rouzioux C; Rohr O; Van Lint C
PLoS Pathog; 2015 Jul; 11(7):e1005063. PubMed ID: 26225566
[TBL] [Abstract][Full Text] [Related]
13. Differentiation into an Effector Memory Phenotype Potentiates HIV-1 Latency Reversal in CD4
Kulpa DA; Talla A; Brehm JH; Ribeiro SP; Yuan S; Bebin-Blackwell AG; Miller M; Barnard R; Deeks SG; Hazuda D; Chomont N; Sékaly RP
J Virol; 2019 Dec; 93(24):. PubMed ID: 31578289
[TBL] [Abstract][Full Text] [Related]
14. Shared Mechanisms Govern HIV Transcriptional Suppression in Circulating CD103
Yukl SA; Khan S; Chen TH; Trapecar M; Wu F; Xie G; Telwatte S; Fulop D; Pico AR; Laird GM; Ritter KD; Jones NG; Lu CM; Siliciano RF; Roan NR; Milush JM; Somsouk M; Deeks SG; Hunt PW; Sanjabi S
J Virol; 2020 Dec; 95(2):. PubMed ID: 33115867
[TBL] [Abstract][Full Text] [Related]
15. HSF1 inhibition attenuates HIV-1 latency reversal mediated by several candidate LRAs In Vitro and Ex Vivo.
Timmons A; Fray E; Kumar M; Wu F; Dai W; Bullen CK; Kim P; Hetzel C; Yang C; Beg S; Lai J; Pomerantz JL; Yukl SA; Siliciano JD; Siliciano RF
Proc Natl Acad Sci U S A; 2020 Jul; 117(27):15763-15771. PubMed ID: 32571938
[TBL] [Abstract][Full Text] [Related]
16. Relationship between Measures of HIV Reactivation and Decline of the Latent Reservoir under Latency-Reversing Agents.
Petravic J; Rasmussen TA; Lewin SR; Kent SJ; Davenport MP
J Virol; 2017 May; 91(9):. PubMed ID: 28202759
[TBL] [Abstract][Full Text] [Related]
17. Harmine enhances the activity of the HIV-1 latency-reversing agents ingenol A and SAHA.
Taylor JP; Armitage LH; Aldridge DL; Cash MN; Wallet MA
Biol Open; 2020 Dec; 9(12):. PubMed ID: 33234703
[TBL] [Abstract][Full Text] [Related]
18. In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection.
Tsai P; Wu G; Baker CE; Thayer WO; Spagnuolo RA; Sanchez R; Barrett S; Howell B; Margolis D; Hazuda DJ; Archin NM; Garcia JV
Retrovirology; 2016 May; 13(1):36. PubMed ID: 27206407
[TBL] [Abstract][Full Text] [Related]
19. A targeted reactivation of latent HIV-1 using an activator vector in patient samples from acute infection.
Mann JFS; Pankrac J; Klein K; McKay PF; King DFL; Gibson R; Wijewardhana CN; Pawa R; Meyerowitz J; Gao Y; Canaday DH; Avino M; Poon AFY; Foster C; Fidler S; Shattock RJ; Arts EJ
EBioMedicine; 2020 Sep; 59():102853. PubMed ID: 32654992
[TBL] [Abstract][Full Text] [Related]
20. Activation of Latent HIV-1 T Cell Reservoirs with a Combination of Innate Immune and Epigenetic Regulators.
Palermo E; Acchioni C; Di Carlo D; Zevini A; Muscolini M; Ferrari M; Castiello L; Virtuoso S; Borsetti A; Antonelli G; Turriziani O; Sgarbanti M; Hiscott J
J Virol; 2019 Nov; 93(21):. PubMed ID: 31413127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
